A Slate of Data for Exelixis

For drugmakers like Exelixis (Nasdaq: EXEL  ) that specialize in developing compounds to fight solid tumors, there is no bigger show for their top clinical trial data than the American Society of Clinical Oncology (ASCO) meeting in late May or early June.

Exelixis will present analyses of study data at ASCO for all of its lead cancer-fighting compounds. Phase 1 data for two of Exelixis' more exciting compounds, XL184 and XL765, will be included, as well as more phase 2 data for XL647 and XL880, which were developed in-house -- GlaxoSmithKline (NYSE: GSK  ) took over development of XL880 as a partner in December.

What makes ASCO so important is that many doctors and key opinion leaders in oncology use the event to help form their opinions on these anti-cancer drugs. Drugmakers like ImClone Systems (Nasdaq: IMCL  ) and Onyx Pharmaceuticals (Nasdaq: ONXX  ) often save their best and most exciting clinical trial data for ASCO. This is why frustrated investors often only get to hear "study failed" or "study succeeded" when a drugmaker releases results of a clinical study before a medical conference.

As one biotech executive said, "oncology is a data-driven market," so a drug's success or failure can often depend on the data that a company (and its competitors) showcase at ASCO and the other major conferences. ASCO is not set to begin until May 30 this year, but all investors will have an idea about the quality of the clinical trial data that will be released there.

ASCO will publicly post all of the abstracts for its meeting on its website at 9 p.m. Eastern time on May 15. Expect to see some extreme volatility in Exelixis' and all other ASCO-related drugmakers' stocks as investors digest the data.

Read/Post Comments (0) | Recommend This Article (13)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 612456, ~/Articles/ArticleHandler.aspx, 10/25/2016 9:05:40 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,169.27 -53.76 -0.30%
S&P 500 2,143.16 -8.17 -0.38%
NASD 5,283.40 -26.43 -0.50%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/25/2016 4:00 PM
EXEL $11.30 Up +0.01 +0.09%
Exelixis CAPS Rating: ****
GSK $40.32 Down -0.36 -0.88%
GlaxoSmithKline CAPS Rating: ***
IMCL $69.99 Down +0.00 +0.00%
ImClone Systems CAPS Rating: **
ONXX.DL $0.00 Down +0.00 +0.00%
Onyx Pharmaceutica… CAPS Rating: **